Raju Kucherlapati

Raju Kucherlapati is Scientific Director, Harvard-Partners Center for Genetics and Genomics, Paul C. Cabot Professor of Genetics, Harvard Medical School, and Professor of Medicine, Harvard Medical School. He came to the United States in 1967 after completing undergraduate and graduate degrees in India. He received his Ph.D. from the University of Illinois at Urbana and then fulfilled his post-doctoral work in the lab of Frank Ruddle at Yale University. He was Assistant Professor in the Department of Biochemical Sciences at Princeton University, and then became Professor in the Department of Genetics at the University of Illinois College of Medicine. In 1989 Dr. Kucherlapati went to the Albert Einstein College of Medicine where he was the Lola and Saul Kramer Professor of Molecular Genetics and University Chairman of the Department of Molecular Genetics, a position he held for eleven years. In 2001 Dr. Kucherlapati became Professor of Medicine and the Paul C. Cabot Professor of Genetics at Harvard Medical School as well as the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics.

Dr. Kucherlapati's research interests include human and mouse genetics and genomics and the cloning of human disease genes and the generation and characterization of mouse models for human disease. The Kucherlapati laboratory was involved in the mapping and sequencing of the human genome with particular focus on human chromosome 12. He was also a member of the consortium to map and sequence the human and mouse genomes. Dr. Kucherlapati identified many human disease genes including those responsible for Velo-cardio-facial syndrome and Noonan Syndrome. Together with Dr. Oliver Smithies, Dr. Kucherlapati developed methods for gene targeting in mammalian cells and he has used these approaches to develop a very large number of mouse models for human disease with particular emphasis on cancer. To date he holds 12 patents. He was a member of the National Advisory Council for Human Genome Research at the National Human Genomics Research Institute, and was co-chair of the steering committee for the National Cancer Institute’s Mouse Models for Human Cancer Consortium. He served on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics.

Dr. Kucherlapati was a founder of Cell Genesys, Abgenix, Aveo Pharmaceuticals and Millennium Pharmaceuticals. He currently serves on the board of Millennium Pharmaceuticals and on the board of privately held AVEO Pharmaceuticals.